(Q35105717)

6 August 2017

1 reference

title

Hepatitis C in the HIV-infected patient. (English)

1 reference

6 August 2017

1 reference

1 reference

1

Mark S Sulkowski

1 reference

6 August 2017

2

David L Thomas

1 reference

6 August 2017

publication date

1 February 2003

1 reference

6 August 2017

published in

Clinics in liver disease

1 reference

6 August 2017

volume

7

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

179-194

1 reference

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Incidence and risk factors for hepatitis C among injection drug users in Baltimore, Maryland

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Transfusion-associated hepatitis and AIDS. What is the risk?

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Risk factors for seroconversion to human immunodeficiency virus among male homosexuals. Results from the Multicenter AIDS Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore--an analysis of 309 sex partnerships

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Risk for Non-A, Non-B (Type C) Hepatitis through Sexual or Household Contact with Chronic Carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Hepatitis C virus infection in sexually active homosexual men.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Antibody to Hepatitis C Virus among Cardiac Surgery Patients, Homosexual Men, and Intravenous Drug Users in Baltimore, Maryland

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Increased vertical transmission of human immunodeficiency virus from hepatitis C virus-coinfected mothers. Women and Infants Transmission Study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Protection against persistence of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

The natural history of hepatitis C virus infection: host, viral, and environmental factors

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Outcome of hospital care of liver disease associated with hepatitis C in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Determinants of the quantity of hepatitis C virus RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Severe hepatic failure related to nevirapine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients?

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Hepatitis C and progression of HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Hepatitis C virus (HCV) viremia in human immunodeficiency virus-seronegative and -seropositive patients with indeterminate HCV recombinant immunoblot assay

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

A long-term study of hepatitis C virus replication in non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Liver biopsy findings in 501 patients infected with human immunodeficiency virus (HIV).

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

The role of liver biopsy in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Fulminant Hepatitis Associated with Hepatitis A Virus Superinfection in Patients with Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. Comité des Anti-Viraux

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Does HIV-infection influence the response of chronic hepatitis C to interferon treatment? A French multicenter prospective study. French Multicenter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Response to treatment of chronic hepatitis C with interferon α in patients infected with HIV-1 is associated with higher CD4+ cell count

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Chronic hepatitis C in HIV infection: feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Interferon and ribavirin combination therapy for chronic hepatitis C in human immunodeficiency virus-infected patients with congenital coagulation disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Human immunodeficiency virus infection, anemia, and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Ribavirin antagonizes the effect of azidothymidine on HIV replication

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Solid organ transplantation in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

Mother-to-Child Transmission of the Human Immunodeficiency Virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2802%2900074-0

7 January 2021

10.1016/S1089-3261(02)00074-0

Identifiers

DOI

1 reference

6 August 2017

1 reference